MAIA is an immuno-oncology company focused on the development and commercialization of potential first-in-class drugs that are intended to meaningfully improve and extend the lives of people with hard-to-treat cancers. We are exploring a new science for cancer therapy utilizing a novel dual mechanism of action: telomere targeting and immunogenicity. Our lead program is THIO, a first-in-class anticancer agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with telomerase-positive cancer cells.